Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22393599 | 0.77 | HTR2A (0.42) | HTR2APRCPSIGMAR1ANPEPKDM1A | |
| SCHEMBL21887274 | 0.76 | HTR2A (0.41) | HTR2APRCPSIGMAR1ANPEPKDM1A | |
| SCHEMBL25803231 | 0.75 | PTPN11 (0.36) | PTPN11 | |
| SCHEMBL22393733 | 0.72 | HTR2A (0.38) | HTR2APRCPKDM1A | |
| SCHEMBL2793129 | 0.71 | HTR2A (0.43) | HTR2ASIGMAR1ANPEPKDM1A | |
| SCHEMBL21845156 | 0.71 | HTR2A (0.43) | HTR2ASIGMAR1ANPEPKDM1A | |
| SCHEMBL24389159 | 0.69 | HTR2A (0.38) | HTR2ASIGMAR1KDM1A | |
| SCHEMBL24388765 | 0.68 | HTR2A (0.41) | HTR2ASIGMAR1ANPEPKDM1A | |
| SCHEMBL23811378 | 0.68 | HTR2A (0.41) | HTR2ASIGMAR1ANPEPKDM1A | |
| SCHEMBL27761866 | 0.67 | HTR2A (0.43) | HTR2AANPEPKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | PTPN5, PTPN1, PTPN2 | HTR2A 2901/4885PRCP 489/4885PTPN11 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.